H

Authors :: Yukinari, Kato
Tomokazu, Ohishi
Masato, Sano
Teizo, Asano
Yusuke, Sayama
Junko, Takei
Manabu, Kawada
Mika K, Kaneko
Source :: Monoclonal antibodies in immunodiagnosis and immunotherapy. 39(3)
Publication Year :: 2020
Abstract: Overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in breast cancer, gastric, lung, colorectal, oral, and pancreatic cancers. HER2 expression is associated with poor clinical outcomes. An anti-HER2 humanized antibody, trastuzumab, has improved survival rates in patients with HER2-overexpressing breast and gastric cancers. Previously, we established a novel anti-HER2 monoclonal antibody (mAb), H